These findings strongly support the alternative hypothesis that SGLT2 inhibitors might have one or more independent, and still unknown, activities not restricted to the kidney, and this could explain not only their “hyperglycemia-independent” renal effects but also their extra-renal effects that have been recently demonstrated. Here, SLC5A2 is linked to Hyperglycemia.